The Break Up Big Medicine Act, which Cuban has publicly endorsed, would target insurer ownership of PBMs, provider groups and drug distribution networks. Supporters said such vertical integration will allow large health care conglomerates to control multiple points in the value chain, steer patients toward affiliated entities, and use internal transfer pricing to mask true costs. That can make it difficult to see whether savings from scale are being passed on or captured as profit, according to the report.
